Patent ID: 6949259

Claim:
A solid preparation comprising 0.25 to 5 mg of (±)-5-[(2,4-dioxo-thiazolidine-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]-methyl]benzamide as an active ingredient and at least one carrier, wherein said solid preparation is suitable for oral administration and wherein (±)-5-[(2,4-dioxo-thiazolidine-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]-methyl]benzamide is uniformly contained in said solid preparation thereby making (±)-5-[(2,4-dioxo-thiazolidine-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]-methyl]benzamide easy to orally administer, wherein the solid preparation is prepared by mixing 0.25 to 5 mg of (±)-5-[(2,4-dioxo-thiazolidine-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]-methyl]benzamide, lactose, crystalline cellulose, and low substituted hydroxypropylcellulose to obtain a mixture; granulating with drying in the presence of an aqueous solution of polyvinyl alcohol with a fluidized bed granulator to obtain a granulated product; then mixing the granulated product with magnesium stearate after screening and rectifying the granules from the granulator to obtain a second mixture; and pressing the second mixture into a tablet.